Cargando…

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma

BACKGROUND: The impact of neoadjuvant chemoradiotherapy (nCRT) on early stage esophageal cancer is unknown. Here, we compared the outcomes after esophagectomy alone or nCRT plus surgery for clinically staged node‐negative esophageal cancer. METHODS: We searched the Surveillance, Epidemiology, and En...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Hui‐Jiang, Wei, Yu‐Cheng, Gong, Lei, Ge, Nan, Han, Bin, Shi, Guo‐Dong, Yu, Zhen‐Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471040/
https://www.ncbi.nlm.nih.gov/pubmed/32755068
http://dx.doi.org/10.1111/1759-7714.13586
_version_ 1783578698383884288
author Gao, Hui‐Jiang
Wei, Yu‐Cheng
Gong, Lei
Ge, Nan
Han, Bin
Shi, Guo‐Dong
Yu, Zhen‐Tao
author_facet Gao, Hui‐Jiang
Wei, Yu‐Cheng
Gong, Lei
Ge, Nan
Han, Bin
Shi, Guo‐Dong
Yu, Zhen‐Tao
author_sort Gao, Hui‐Jiang
collection PubMed
description BACKGROUND: The impact of neoadjuvant chemoradiotherapy (nCRT) on early stage esophageal cancer is unknown. Here, we compared the outcomes after esophagectomy alone or nCRT plus surgery for clinically staged node‐negative esophageal cancer. METHODS: We searched the Surveillance, Epidemiology, and End Results database for patients with clinically node‐negative (cN0) esophageal cancer from 2004 to 2016 who underwent surgery alone or nCRT plus surgery. Propensity score matching and Cox regression analysis were used to identify covariates associated with overall survival and cancer‐specific survival. RESULTS: A total of 1587 patients were retrospectively identified, of whom 49.8% (n = 791) received nCRT and 80.2% (n = 1273) were truly node‐negative diseases. For the entire cohort, surgery alone was associated with a statistically significant but modest absolute increase in survival outcomes (P < 0.01). After matching, nCRT was associated with improved five‐year overall survival for pT3‐4N0 (localized) disease (59.6% vs. 37.7%; P < 0.001) and pathological node‐positive disease (60.5% vs. 40.7%; P = 0.002). Cox multivariate regression analysis revealed that the addition of nCRT for truly node‐negative patients with tumor length ≥ 3 cm, pT1‐2N0 (early‐staged) and localized disease were independent risk factors for survival than surgery alone (P < 0.01). CONCLUSIONS: Compared with surgery alone, patients with cN0 esophageal cancer with pathological node‐positive or localized true node‐negative disease gain a significant survival benefit from nCRT. However, nCRT plus surgery was associated with decreased survival for early‐staged true node‐negative patients. This finding may have significant implications on the use of neoadjuvant chemoradiation in patients with cN0 disease.
format Online
Article
Text
id pubmed-7471040
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-74710402020-09-11 Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma Gao, Hui‐Jiang Wei, Yu‐Cheng Gong, Lei Ge, Nan Han, Bin Shi, Guo‐Dong Yu, Zhen‐Tao Thorac Cancer Original Articles BACKGROUND: The impact of neoadjuvant chemoradiotherapy (nCRT) on early stage esophageal cancer is unknown. Here, we compared the outcomes after esophagectomy alone or nCRT plus surgery for clinically staged node‐negative esophageal cancer. METHODS: We searched the Surveillance, Epidemiology, and End Results database for patients with clinically node‐negative (cN0) esophageal cancer from 2004 to 2016 who underwent surgery alone or nCRT plus surgery. Propensity score matching and Cox regression analysis were used to identify covariates associated with overall survival and cancer‐specific survival. RESULTS: A total of 1587 patients were retrospectively identified, of whom 49.8% (n = 791) received nCRT and 80.2% (n = 1273) were truly node‐negative diseases. For the entire cohort, surgery alone was associated with a statistically significant but modest absolute increase in survival outcomes (P < 0.01). After matching, nCRT was associated with improved five‐year overall survival for pT3‐4N0 (localized) disease (59.6% vs. 37.7%; P < 0.001) and pathological node‐positive disease (60.5% vs. 40.7%; P = 0.002). Cox multivariate regression analysis revealed that the addition of nCRT for truly node‐negative patients with tumor length ≥ 3 cm, pT1‐2N0 (early‐staged) and localized disease were independent risk factors for survival than surgery alone (P < 0.01). CONCLUSIONS: Compared with surgery alone, patients with cN0 esophageal cancer with pathological node‐positive or localized true node‐negative disease gain a significant survival benefit from nCRT. However, nCRT plus surgery was associated with decreased survival for early‐staged true node‐negative patients. This finding may have significant implications on the use of neoadjuvant chemoradiation in patients with cN0 disease. John Wiley & Sons Australia, Ltd 2020-08-04 2020-09 /pmc/articles/PMC7471040/ /pubmed/32755068 http://dx.doi.org/10.1111/1759-7714.13586 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Gao, Hui‐Jiang
Wei, Yu‐Cheng
Gong, Lei
Ge, Nan
Han, Bin
Shi, Guo‐Dong
Yu, Zhen‐Tao
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma
title Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma
title_full Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma
title_fullStr Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma
title_full_unstemmed Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma
title_short Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma
title_sort neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471040/
https://www.ncbi.nlm.nih.gov/pubmed/32755068
http://dx.doi.org/10.1111/1759-7714.13586
work_keys_str_mv AT gaohuijiang neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma
AT weiyucheng neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma
AT gonglei neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma
AT genan neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma
AT hanbin neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma
AT shiguodong neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma
AT yuzhentao neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma